| Modality | Indication | Current Stage | Development Partners | ||||
|---|---|---|---|---|---|---|---|
| Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | |||
| Cancer | |||||||
| Vaccine | Breast Cancer |
|
|
|
|
||
| Vaccine | Ovarian Cancer |
|
|
|
|||
| Vaccine | Lung, Colon, and Prostate Cancers |
|
|
||||
| CAR-T | Ovarian Cancer |
|
|
|
|
||
| CAR-T | Other solid tumors |
|
|
||||
Latest News & Events
Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Read More...Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance
Read More...Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy
Read More...